Press Releases

Copiague, January 22, 2002
American Biogenetic Sciences Secures Vaccine Agreements With Russian Federation Entities

Copiague, January 9, 2002
American Biogenetic Sciences Updates Information and Proceeds with Vaccine Aggreements

Copiague, January 9, 2002
American Biogenetic Sciences Voluntarily Delists From NASDAQ and Intends to Apply to the OTC Bulletin Board

Copiague, November 28, 2001
American Biogenetic Sciences, Inc. Responds to Inquiries

Mowsow, Russia, New York, USA, November 26, 2001
ABS Negotiates Landmark Anthrax and Smallpox vaccine Agreement

Copiague, November 9, 2001
Abbott Discontinues Liscensing Agreement

Copiague, September 25, 2001
ABS Awarded Patent for Treating and Preventing Migraine

Copiague, August 29, 2001
Biotechnology Value Fund Expands Investment in American Biogenetic Sciences, Inc.

Copiague, July 19, 2001
American Biogenetic Sciences TpP™ Test Studies Reported At Paris Conference

Copiague, July 13, 2001
American Biogenetic Sciences Inc. Receives NASDAQ Staff Determination Letter

Copiague, July 2, 2001
American Biogenetic Sciences Inc. Sells Assets of its Subsidiary, Stellar Bio Systems, Inc.

Copiague, May 24, 2001
American Biogenetic Sciences Issues 2000 Annual Report

Copiague, May 21, 2001
Recent Clinical Studies Further Validates American Biogenetic Sciences TpP™ Test

Copiague, April 23, 2001
American Biogenetic Sciences, Inc. Panel Reviews Antibody Technology at International Meeting of Immunologists

Copiague, April 3, 2001
Biosite® Diagnostics and American Biogenetic Sciences sign a Research and License Agreement for TpP

Copiague, February 13, 2001
American Biogenetic Sciences, Inc. Obtains U.S. Patent for the Treatment of Malignant and Benign Tumors

Copiague, February 5, 2001
American Biogenetic Sciences, Inc. New President Highlights Progress in 2000 and Business Outlook for 2001

Copiague, January 11, 2001
American Biogenetic Sciences, Inc. Announces Management Team Transition and New Appointments to the Board

Newsday Article - November 6, 2000
An Entrepreneur for the Ages At 85, Alfred Roach is still trying to innovate technology

Copiague,- October 3, 2000
Framingham Heart Study Shows ABS Diagnostic FiF Test Results Demonstrate a Stronger Association with Cardiovascular Disease Risk than Traditional Test Methods

Copiague,- September 27, 2000
American Biogenetic Sciences Named Fastest Growing Company in the 2000 Long Island Technology Fast 50

Copiague,- July 19, 2000
American Biogenetic Sciences, Inc. Announces Recent Publication Affirms TpP Superiority in Evaluating Deep Vein Thrombosis and Pulmonary Embolism

Copiague,- July 13, 2000
American Biogenetic Sciences, Inc. Expands Its Therapeutic Product Pipeline

Copiague,- July 11, 2000
American Biogenetic Sciences, Inc. Reinstated to NASDAQ SmallCap Market

Copiague,- June 28, 2000
American Biogenetic Sciences, Inc. Obtains U.S. Patent for Unique Radionuclide-Labeling Method for MH-1 and Other Monoclonal Antibodies

Copiague,- June 5, 2000
American Biogenetic Sciences, Inc. Announces a Program to Accelerate Development of ABS-205 for Treatment of Alzheimer's Disease

Copiague,- May 4, 2000
American Biogenetic Sciences and Trevigen Have Generated a New Way to Measure DNA Damage

Copiague,- March  22, 2000
American Biogenetic Sciences, Inc. to Humanize Its Unique Monoclonal Antibody

Copiague,- March  7, 2000
American Biogenetic Sciences, Inc. to Provide Unique Monoclonal Antibodies to the Pharmaceutical and Biotechnology Industry

Copiague,- March  2, 2000
American Biogenetic Sciences's Neuroscience Compound Will Be Studied in Alzheimer's Model

Copiague,- February  17, 2000
NASDAQ Agrees to Review Listing Status for American Biogenetics Sciences, Inc.

Copiague,- February  10, 2000
American Biogenetic Sciences, Inc. Receives $3.0 Million Investment From Biotechnology Value Fund, L.P.

Copiague,- February  3, 2000
American Biogenetic Sciences Diagnostic Test May Prove to be Novel Marker for Life Threatening Complication of Pregnancy

Copiague,- January  27, 2000
Abbott Laboratories and American Biogenetic Sciences Sign Agreement to License Novel Neuroscience Compound

Copiague,- January  11, 2000
MABA is the New Symbol for American Biogenetic Sciences, Inc. on OTC Bulletin Board

Copiague,- January  7, 2000
American Biogenetic Sciences, Inc. NASDAQ Smallcap Market Listing Extension Denied

Copiague,- December  31, 1999
American Biogenetic Sciences, Inc. Seeks Extension of NASDAQ Exception

Copiague,- December  3, 1999
American Biogenetic Sciences, Inc. Receives Extension on Market Listing

Copiague,- July  21, 1999
American Biogenetic Sciences Signs Breakthrough Agreement with the Chinese Academy of Medical Sciences to Market and Sell Traditional Chinese Medicines Worldwide

Copiague,- July  14, 1999
American Biogenetic Sciences and Chinese Academy Join Forces on Transgenic Quest

Copiague,- June  2, 1999
Study Finds American Biogenetic Sciences' TpP™ Test 97% Accurate in Excluding Deep Vein Thrombosis

Copiague,- May  10, 1999
American Biogenetic Sciences' TpP™ Test Identifies Patients with Underlying Clotting Defects

Copiague,- May  6, 1999
Japanese Patent Granted on American Biogenetic Sciences' Next-Generation Valproic Acid

Copiague,- April  6, 1999
American Biogenetic Sciences' Point of Care TpP Test to Proceed to Clinical Evaluation

Copiague,- March  9, 1999
American Biogenetic Sciences, Inc Appoints former Merck Senior Executive to Board of Directors.

Copiague,- February 24, 1999
American Biogenetic Sciences, Inc uses Chiral Technology to Produce Single Isomer Version of Epilepsy Drug ABS-103.

Copiague,- February 17, 1999
American Biogenetic Sciences, Inc in Full Compliance with NASDAQ Requirements.

Copiague,- February 4, 1999
American Biogenetic Sciences, Inc Engages Investor Relations Firm Redington, Inc.

Copiague,- February 3, 1999
American Biogenetic Sciences, Secures Japanese Notice of Allowance for Patent Application.

Copiague,- January 25, 1999
American Biogenetic Sciences, Inc Signs Agreement with FNG & Associates, Inc.

Copiague,- January 21, 1999
American Biogenetic Sciences, Inc Appoints Dr. Yale Arkel Coordinator of Clinical Development.

Copiague,- January 6, 1999
M.H.Meyerson, Inc Announces Initiated Coverage of ABS.

 


American Biogenetic Sciences, Inc. ©2000, 2001